百诚医药
(301096)
| 流通市值：47.10亿 | | | 总市值：62.14亿 |
| 流通股本：8278.72万 | | | 总股本：1.09亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 332,353,112.78 | 128,727,480.49 | 801,923,244.22 | 721,478,652.99 |
| 营业收入 | 332,353,112.78 | 128,727,480.49 | 801,923,244.22 | 721,478,652.99 |
| 二、营业总成本 | 336,557,099.34 | 164,765,613.68 | 809,886,835.1 | 580,693,571.16 |
| 营业成本 | 163,735,104.78 | 75,155,234.89 | 385,064,413.67 | 280,152,584.31 |
| 税金及附加 | 4,632,301.02 | 2,311,339.19 | 9,896,834.04 | 7,411,486.72 |
| 销售费用 | 5,720,791.43 | 2,590,098.2 | 14,961,617.19 | 11,341,706.52 |
| 管理费用 | 53,967,967.42 | 26,799,539.51 | 77,469,868.54 | 45,403,661.43 |
| 研发费用 | 100,966,474.15 | 54,466,161.55 | 318,288,767.42 | 235,051,331.05 |
| 财务费用 | 7,534,460.54 | 3,443,240.34 | 4,205,334.24 | 1,332,801.13 |
| 其中:利息费用 | 9,591,444.49 | 4,309,725.63 | 17,053,061.59 | 12,108,878.84 |
| 其中:利息收入 | 2,161,769.83 | 923,672.36 | 13,040,572.27 | 10,912,287.29 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 1,688,430.57 | 1,080,147.13 | -5,591,708.21 | -6,585,922.87 |
| 资产处置收益 | - | 0 | - | - |
| 资产减值损失(新) | 937,128.96 | -172,401.47 | -10,090,018.4 | -6,254,575.47 |
| 信用减值损失(新) | -7,665,710.17 | -1,561,621.59 | -30,910,130.55 | -13,856,953.86 |
| 其他收益 | 12,929,850.36 | 8,778,823.2 | 20,161,860.2 | 16,746,347.58 |
| 四、营业利润 | 3,685,713.16 | -27,913,185.92 | -34,393,587.84 | 130,833,977.21 |
| 加:营业外收入 | 240,566.96 | 151,547.07 | 400,763.65 | 281,683.76 |
| 减:营业外支出 | 25,794.03 | 22,411.79 | 2,068,148.36 | 400,255.35 |
| 五、利润总额 | 3,900,486.09 | -27,784,050.64 | -36,060,972.55 | 130,715,405.62 |
| 减:所得税费用 | 802,325.55 | -1,586,432.83 | 16,862,018.54 | -10,822,213.02 |
| 六、净利润 | 3,098,160.54 | -26,197,617.81 | -52,922,991.09 | 141,537,618.64 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 3,098,160.54 | -26,197,617.81 | -52,922,991.09 | 141,537,618.64 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 3,098,160.54 | -26,197,617.81 | -52,742,809.58 | 141,656,133.34 |
| 少数股东损益 | 0 | - | -180,181.51 | -118,514.7 |
| 扣除非经常损益后的净利润 | -11,730,144.55 | -36,182,304.38 | -72,631,801.94 | 124,998,039.63 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.03 | -0.24 | -0.49 | 1.31 |
| (二)稀释每股收益 | 0.03 | -0.24 | -0.49 | 1.31 |
| 八、其他综合收益 | -30,111.11 | -32,349.31 | -6,882.64 | 2,248.55 |
| 归属于母公司股东的其他综合收益 | -30,111.11 | -32,349.31 | -6,882.64 | 2,248.55 |
| 九、综合收益总额 | 3,068,049.43 | -26,229,967.12 | -52,929,873.73 | 141,539,867.19 |
| 归属于母公司股东的综合收益总额 | 3,068,049.43 | -26,229,967.12 | -52,749,692.22 | 141,658,381.89 |
| 归属于少数股东的综合收益总额 | - | - | -180,181.51 | -118,514.7 |
| 公告日期 | 2025-08-27 | 2025-04-23 | 2025-04-23 | 2024-10-29 |
| 审计意见(境内) | | | 标准无保留意见 | |